Confo Therapeutics
Business Services · Belgium · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Technologiepark-zwijnaarde 30, Gent, Fla...Phone Number
+32 93967400Website
www.confotherapeutics.comRevenue
$13.5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Confo Therapeutics
Confo Therapeutics is a clinical-stage company and leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs). It discovers small molecules and antibodies with the desired pharmacology by employing its proprietary discovery platform.Explore more
Confo Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Confo Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Confo Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Confo Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Confo Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Confo Therapeutics
Check if Confo Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Confo Therapeutics had a recent Job posting/layoffs
Confo Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Confo Therapeutics is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Confo Therapeutics as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Confo Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Confo Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Confo Therapeutics.
Confo Therapeutics financials insights
Gather financial insights about Confo Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$33.4M
2024
Series B
$65M
Confo Therapeutics Tech Stack
A closer look at the technologies used by Confo Therapeutics
Most Recent Scoops
Open Position
Open Position
Funding
Funding
New Hire
Executive Move
Executive Move
Board of Directors
Confo Therapeutics News & Media
Confo Therapeutics Announces Phase 2 Clinical Trial Initiation by Lilly for Peripheral Pain Candidate, CFTX-1554
Confo Therapeutics announces the Phase 2a clinical trial initiation by Eli Lilly and Company for CFTX-1554 in peripheral pain.Confo Therapeutics Nominates SSTR5 Agonist Antibody CFTX-2034 as Development Candidate for Post-Bariatric Hypoglycemia
Confo Therapeutics nominates SSTR5 agonist antibody CFTX-2034 as its development candidate for post-bariatric hypoglycemia (PBH).Confo Therapeutics Awarded VLAIO Grant for Development of Ultra-Long-Acting Antibody-Based GPCR Therapeutics in Endocrine and Metabolic Conditions
Ghent, Belgium – October 8, 2025 – Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), announced today that it has secured a EUR 1 million grant from Flanders Innovation & Entrepreneurship (VLAIO). Confo will use this 2-year grant to advance research and development of ultra-long-acting medicines targeting GPCRs, including bi- and multi-specific antibody formats, built on its proprietary, patent-protected platform. These next-generationConfo Therapeutics Announces Publication in Nature Communications Demonstrating First-Ever Structure of a Complex Between an Antibody-based Agonist and a Class A GPCR Regulating Hunger and Satiety
GHENT, Belgium--(BUSINESS WIRE)--Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), today announced a publication in Nature Communications demonstrating the world’s first structure of a complex between an antibody-based agonist and a Class A GPCR, specifically the melanocortin receptor 4 (MC4R). MC4R belongs to the melanocortin receptor family of GPCRs and is a key switch in the leptin-melanocortin molecular axis that controls hunger
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Confo Therapeutics
Sign Up For FreeTo access detailed company insights
Confo Therapeutics is a clinical-stage company and leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs). It discovers small molecules and antibodies with the desired pharmacology by employing its proprietary discovery platform.... Read More
